The idea of removing senescent cells – those old, tired cells that cease to divide – from the body to rid the body of harmful proteins was one of the outstanding advances in anti-aging. Now that the Mayo Clinic has generated a stream of animal data to substantiate the hypothesis, there are now results from an early human study showing that medicines have been found that can do just that. Latonya Hickson The Phase I study should not reveal the effects of decreasing aging cells in the body. Rather, scientists wanted to show that a senolysis scheme they tested on mice works the same way in humans. The clearance of senescent cells by senololytic agents has not been directly demonstrated in peer-reviewed published human clinical trials, "they said Authors in EBioMedicine .
For the small study, researchers used dasatinib and quercetin; The former is a cancer drug, also called Sprycel, while the latter is a herbal derivative. Nine patients with diabetes-related chronic kidney disease were recruited and treated for three days.
While the drugs were eliminated from the system within a few days, the effects seemed to be persistent. with LaTonya Hickson and Larissa Langhi Prata as co-authors – reported:
Key markers for senescent cell loading were reduced in adipose tissue and skin taken by subjects 11 days after completion of the three-day D + Q treatment
such evidence on the mechanism of action underpins their earlier work and suggests that a brief dose of dasatinib plus quercetin improves the physical function of patients with idiopathic pulmonary fibrosis – a difficult task to treat.
Wh In a nutshell, the study is a major step forward in translating senolo- gic therapies, said Ronald Kohanski, deputy director of the Department of Aging Biology at the National Institute of Aging.
Reduction in two tissues in humans is an important advance, based on convincing evidence from studies in laboratory mice. "
Chronic kidney disease is just one of many age-related diseases that can occur The team believes that senolytics can delay, prevent or treat, said senior author James Kirkland (who runs the aging center of Robert and Arlene Kogod) a big difference 04] In the event that someone is overly excited, the scientists felt the need to end their work with caution:
The field of senolytics is new. The first clinical study with senolytic agents was published in January 2019. The results reported here are preliminary findings from an ongoing clinical trial of senolytic agents for the treatment of dysfunction in patients with diabetic chronic renal disease. To date, fewer than 150 subjects have been treated with these drugs in clinical trials. In addition to side effects associated with individual senolytic drugs known from other contexts in which these drugs have been used, serious side effects of senolytics may be a class that are not yet known. We warn against the use of senolytics outside the scope of clinical trials until more is known about their effects and side effects.